« Return to News | Technology Solutions

Trifecta Clinical, SAFE-BioPharma partner

Friday, September 20, 2013 10:37 AM

Trifecta Clinical, a global clinical technology solutions provider, has partnered with SAFE-BioPharma to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.

“SAFE-BioPharma digital identity credentials will enhance Trifecta’s ability to quickly and securely exchange data with sponsors, CROs and consortiums, saving money and time. It will simplify complicated processes for our clients as well as investigators,” said Alden Meier, president of Trifecta Clinical.

The SAFE-BioPharma standard was established by the pharmaceutical industry with the participation of the EMA and the FDA to create and maintain an interoperable digital identity and signature standard that allows secure, trusted exchanges and legally-binding digital signatures. A distinguishing characteristic of the standard requires each digital identity to be closely bound to its user’s proven identity. This provides a high level of trust in the identity of its user and is the basis of its interoperability. SAFE-BioPharma identity credentials will be trusted by U.S. government agencies such as the NIH, FDA and other systems that are directly or indirectly cross-certified with SAFE-BioPharma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.